Collaborations - Additional Information (Details) - USD ($)			3 Months Ended		12 Months Ended
	Jul. 07, 2020	May 09, 2019	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cost reimbursement payment received			$ 2,500,000
Unbilled accounts receivable			3,300,000
Research and development			$ 42,227,000	$ 35,944,000
Remaining research term of collaboration			2 years 9 months 18 days
Revenue recognized			$ 9,466,000	9,622,000
Sanofi Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 150,000,000.0
Collaboration agreement transaction price	150,000,000.0
Revenue recognized recorded in deferred revenue			7,700,000
Unsatisfied performance obligation			50,500,000		$ 54,900,000
Milestone receivable			0
Research and development			0
Revenue recognized			7,700,000	6,600,000	5,500
Sanofi Agreement | Collaboration Target 1
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price	120,000,000.0
Revenue recognized recorded in deferred revenue			7,100,000	4,200,000
Sanofi Agreement | Collaboration Target 2
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price	30,000,000.0
Revenue recognized recorded in deferred revenue			600,000
Revenue recognized				2,400,000
Sanofi Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments	1,480,000,000
Commercial Milestone Payments	700,000,000.0
Sanofi Agreement | Minimum | IRAK4 Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestone payments	1,000,000,000.0
Commercial Milestone Payments	$ 400,000,000.0
Vertex Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized recorded in deferred revenue			1,800,000
Unsatisfied performance obligation			6,600,000		$ 8,400,000
Initial research term of collaboration		4 years
Extended research term of collaboration		1 year
Revenue recognized			$ 1,800,000	$ 3,000,000.0
Vertex Agreement | Series B-1 Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price		$ 55,900,000
Non refundable upfront payment received		$ 50,000,000.0
Issuance of shares, Shares		3,059,695
Stock issued price per share		$ 6.54
Preferred stock premium		$ 5,900,000
Vertex Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Eligible to receive payments including development, regulatory and commercial milestones		$ 170,000,000.0